Jounce Therapeutics Enters Into Agreement to Be Acquired by - GlobeNewswire
2023-03-27 • Google News
Jounce Therapeutics Inc (JNCE)
US$ 1.2211.93%
Price Chart
Key Statistics
Market Cap
$ 101.59M
P/E Ratio
0.00
Revenue (TTM)
$ 82M
Volume
1.85M
52W High
$ 0.00
52W Low
$ 0.00
Dividend Yield
0.00%
Beta
0.75
Technicals
50-Day MA
1.6398
200-Day MA
1.9273
52 Week High
N/A
52 Week Low
N/A
About JNCE
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer.
Employees
141
Headquarters
Cambridge, MA
CEO
Dr. Richard Murray Ph.D.
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg